Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells $64,170.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,139 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total value of $64,170.00. Following the sale, the chief financial officer directly owned 70,314 shares in the company, valued at $2,109,420. This trade represents a 2.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

Shares of PGNY traded up $0.47 during midday trading on Friday, hitting $34.84. 1,420,642 shares of the company traded hands, compared to its average volume of 1,365,733. The stock has a 50-day moving average of $27.27 and a 200-day moving average of $24.54. Progyny, Inc. has a one year low of $16.10 and a one year high of $35.50. The firm has a market cap of $2.67 billion, a P/E ratio of 31.96, a PEG ratio of 2.08 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last posted its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.23%. The business had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same quarter in the prior year, the firm posted $0.15 EPS. Progyny’s revenue was up 8.9% on a year-over-year basis. Sell-side analysts forecast that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Progyny

Several institutional investors have recently added to or reduced their stakes in PGNY. BlackRock Inc. bought a new position in shares of Progyny during the second quarter valued at about $334,426,000. Bank of America Corp DE grew its stake in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares during the last quarter. William Blair Investment Management LLC purchased a new position in Progyny during the 2nd quarter valued at about $16,807,000. Principal Financial Group Inc. increased its holdings in Progyny by 16.4% during the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock valued at $9,422,000 after purchasing an additional 78,198 shares during the period. Finally, Danske Bank A S purchased a new position in Progyny during the 2nd quarter valued at about $15,243,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of research analyst reports. KeyCorp upped their target price on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Wells Fargo & Company boosted their price target on shares of Progyny from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday. Citigroup reaffirmed a “market outperform” rating on shares of Progyny in a report on Thursday. Finally, Barclays cut their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 12th. Eleven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average price target of $34.92.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.